Long term drug delivery devices with polyurethane based polymers and their manufacture
View Patent ↗This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises: 1. a reservoir, said reservoir comprising; 2. at least one active ingredient; and, optionally, 3. at least one pharmaceutically acceptable carrier; a polyurethane based polymer completely surrounding the reservoir.
1. A method of delivering one or more active ingredients to a subject, comprising implanting an implantable drug delivery device into the subject, in which the implantable drug delivery device comprises a polyurethane-based polymer configured to provide a cylindrically shaped reservoir and deliver the one or more active ingredients to the subject by diffusion through the polyurethane-based polymer for a period of six weeks or more from the time of implantation, wherein the reservoir is sealed after being charged with an effective amount of a solid formulation comprising the one or more active ingredients, wherein both the one or more active ingredients and the polyurethane-based polymer exhibit hydrophilic characteristics, and wherein the implantable drug delivery device delivers the one or more active ingredients to the subject at a substantially zero order release rate as measured in vitro.
2. The method of claim 1 , wherein the polyurethane based polymer is selected from the group consisting of thermoplastic polyurethane and thermoset polyurethane.
3. The method of claim 2 , wherein the thermoplastic polyurethane comprises macrodiols, diisocyanates, difunctional chain extenders, or mixtures thereof.
4. The method of claim 2 , wherein the thermoset polyurethane comprises multifunctional polyols, diisocyanates, chain extenders or mixtures thereof.
5. The method of claim 4 , wherein the thermoset polyurethane comprises a polymer chain and cross-linking members, said thermoset polyurethane further including unsaturated bonds in the polymer chains and crosslinkers, initiators, or both as cross-linking members.
6. The method of claim 1 , wherein the polyurethane comprises a hydrophilic pendant group selected from the group consisting of: ionic groups, carboxyl groups, ether groups, hydroxyl groups and mixtures of any two or more thereof.
7. The method of claim 1 , wherein the solid formulation includes one or more pharmaceutically acceptable carriers that are not required for the substantially zero order release rate in vitro of the one or more active ingredients through the polyurethane-based polymer.
8. The method of claim 1 , wherein the one or more active ingredients are selected from drugs that can act on the central nervous system, psychic energizers, tranquilizers, anti-convulsants, muscle relaxants, anti-parkinson, analgesic, anti-inflammatory, anesthetic, antispasmodic, muscle contractants, anti-microbials, anti-malarials, hormonal agents, sympathomimetic, cardiovascular, diuretics, and antiparasitic.
9. The method of claim 1 , wherein the one or more active ingredients comprise histrelin.
10. The method of claim 1 , wherein the one or more active ingredients comprise naltrexone.
11. A method of delivering one or more active ingredients to a subject, comprising implanting an implantable drug delivery device into the subject, in which the implantable drug delivery device comprises a polyurethane-based polymer configured to provide a cylindrically shaped reservoir and deliver the one or more active ingredients to the subject by diffusion through the polyurethane-based polymer for a period of six weeks or more from the time of implantation, wherein the reservoir is sealed after being charged with an effective amount of a solid formulation comprising the one or more active ingredients, wherein both the one or more active ingredients and the polyurethane-based polymer exhibit hydrophobic characteristics, and wherein the implantable drug delivery device delivers the one or more active ingredients to the subject at a substantially zero order release rate as measured in vitro.
12. The method of claim 11 , wherein the polyurethane based polymer is selected from the group consisting of thermoplastic polyurethane and thermoset polyurethane.
13. The method of claim 12 , wherein the thermoplastic polyurethane comprises macrodiols, diisocyanates, difunctional chain extenders, or mixtures thereof.
14. The method of claim 12 , wherein the thermoset polyurethane comprises multifunctional polyols, diisocyanates, chain extenders or mixtures thereof.
15. The method of claim 14 , wherein the thermoset polyurethane comprises a polymer chain and cross-linking members, said thermoset polyurethane further including unsaturated bonds in the polymer chains and crosslinkers, initiators, or both as cross-linking members.
16. The method of claim 11 , wherein the solid formulation includes one or more pharmaceutically acceptable carriers that are not required for the substantially zero order release rate in vitro of the one or more active ingredients through the polyurethane-based polymer.
17. The method of claim 11 , wherein the one or more active ingredients are selected from drugs that can act on the central nervous system, psychic energizers, tranquilizers, anti-convulsants, muscle relaxants, anti-parkinson, analgesic, anti-inflammatory, anesthetic, antispasmodic, muscle contractants, anti-microbials, anti-malarials, hormonal agents, sympathomimetic, cardiovascular, diuretics, and antiparasitic.